{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-214186","form_type":"8-K","ticker":"VOR","cik":"0001817229","company_name":"Vor Biopharma Inc.","filed_at":"2024-09-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.639818+00:00","generated_at":"2026-05-31T06:17:35.910398+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vor Bio reports positive trem-cel + Mylotarg data; plans pivotal trial","bullets":["Phase 1/2 VBP101: 18 patients received trem-cel; 10 received Mylotarg as of July 19, 2024 cut-off.","100% engraftment (median 9 days); CD33 editing efficiency median 89%; full myeloid chimerism at Day 28.","Shielding maintained neutrophil/platelet counts across Mylotarg doses 0.5, 1, 2 mg/m^2.","Early relapse-free survival benefit vs high-risk AML comparators; only 4 relapses recorded.","New preclinical ADC VADC45 targeting CD45; IND-enabling studies planned; FDA pivotal trial discussion by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-214186","json":"https://secwatch.observer/filing/0001193125-24-214186.json","markdown":"https://secwatch.observer/filing/0001193125-24-214186.md","text":"https://secwatch.observer/filing/0001193125-24-214186.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817229/000119312524214186/0001193125-24-214186-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817229/000119312524214186/d867599d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:17:35.910398+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}